Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites to be added.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
No
University of Colorado Cancer Center
Aurora, Colorado, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
Dana Farber/Partners Cancer Care
Boston, Massachusetts, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Princess Margaret Hospital
Toronto, Ontario, Canada
Start Date
April 1, 2010
Primary Completion Date
August 1, 2011
Completion Date
December 1, 2012
Last Updated
August 6, 2014
64
ACTUAL participants
ENMD-2076
DRUG
Lead Sponsor
CASI Pharmaceuticals, Inc.
NCT05039801
NCT04550494
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions